Response: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (Diabetes Metab J 2014;38:211-9).
作者信息
Choe EunYeong, Kang Eun Seok
机构信息
Division of Endocrinology and Metabolism, Department of Internal Medicine, International St. Mary's Hospital, Incheon, Korea.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
出版信息
Diabetes Metab J. 2014 Aug;38(4):319-20. doi: 10.4093/dmj.2014.38.4.319.
Abstract
摘要
相似文献
1
Response: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (Diabetes Metab J 2014;38:211-9).回应：二肽基肽酶-4抑制剂对2型糖尿病患者代谢参数的影响（《糖尿病与代谢杂志》2014年；38:211-219）
Diabetes Metab J. 2014 Aug;38(4):319-20. doi: 10.4093/dmj.2014.38.4.319.
2
Letter: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (Diabetes Metab J 2014;38:211-9).信函：二肽基肽酶-4抑制剂对2型糖尿病患者代谢参数的影响（《糖尿病与代谢杂志》2014年；38：211-219）
Diabetes Metab J. 2014 Aug;38(4):317-8. doi: 10.4093/dmj.2014.38.4.317.
3
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9).二肽基肽酶-4抑制剂与肾素-血管紧张素系统阻断剂对糖尿病合并新型冠状病毒肺炎患者临床结局的影响（《糖尿病代谢杂志》2021年；第45卷：第251 - 259页）
Diabetes Metab J. 2021 Jul;45(4):615-616. doi: 10.4093/dmj.2021.0081. Epub 2021 Jul 30.
4
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9).二肽基肽酶-4抑制剂与肾素-血管紧张素系统阻断对糖尿病合并新型冠状病毒肺炎患者临床结局的影响（《糖尿病与代谢杂志》2021年；第45卷：第251 - 259页）
Diabetes Metab J. 2021 Jul;45(4):619-620. doi: 10.4093/dmj.2021.0118. Epub 2021 Jul 30.
5
A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.GLP1R基因变异与2型糖尿病患者对二肽基肽酶-4抑制剂的反应相关。
Medicine (Baltimore). 2016 Nov;95(44):e5155. doi: 10.1097/MD.0000000000005155.
6
The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes.二肽基肽酶-4 抑制剂对 2 型糖尿病患者代谢参数的影响。
Diabetes Metab J. 2014 Jun;38(3):211-9. doi: 10.4093/dmj.2014.38.3.211. Epub 2014 Jun 17.
7
Response: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7).回应：2型糖尿病患者中胰高血糖素样肽-4抑制剂疗效的预测因素（《糖尿病与代谢杂志》2015年；39:342-347）
Diabetes Metab J. 2015 Oct;39(5):446-7. doi: 10.4093/dmj.2015.39.5.446. Epub 2015 Oct 22.
8
The Research Progress of DPP-4 Inhibitors.DPP-4 抑制剂的研究进展。
Mini Rev Med Chem. 2020;20(17):1709-1718. doi: 10.2174/1389557520666200628032507.
9
Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus ( 2019;43:582-9).回应：瑞舒伐他汀单药20毫克与瑞舒伐他汀5毫克和依折麦布10毫克联合治疗对2型糖尿病患者血脂参数的疗效比较（2019年；43:582 - 589）
Diabetes Metab J. 2019 Dec;43(6):915-916. doi: 10.4093/dmj.2019.0213.
10
Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.二肽基肽酶-4抑制剂治疗2型糖尿病的成本效益
Pharmacoeconomics. 2015 Jun;33(6):581-97. doi: 10.1007/s40273-015-0266-y.
本文引用的文献
1
The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes.二肽基肽酶-4 抑制剂对 2 型糖尿病患者代谢参数的影响。
Diabetes Metab J. 2014 Jun;38(3):211-9. doi: 10.4093/dmj.2014.38.3.211. Epub 2014 Jun 17.
2
Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy.二肽基肽酶-4抑制剂的观察性研究：对意大利阿斯利康VCO地区360例患者的真实情况分析
Clin Drug Investig. 2014 Jul;34(7):513-9. doi: 10.1007/s40261-014-0196-z.
3
DPP-4 inhibitors and lipids: systematic review and meta-analysis.DPP-4 抑制剂与血脂：系统评价和荟萃分析。
Adv Ther. 2012 Jan;29(1):14-25. doi: 10.1007/s12325-011-0088-z. Epub 2011 Dec 22.
4
Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.二肽基肽酶-4 抑制剂的药理学：相似性和差异。
Drugs. 2011 Jul 30;71(11):1441-67. doi: 10.2165/11591400-000000000-00000.
5
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.二肽基肽酶-4 抑制剂维达列汀在人体内的作用机制。
Diabetes Obes Metab. 2011 Sep;13(9):775-83. doi: 10.1111/j.1463-1326.2011.01414.x.
6
Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.2 型糖尿病的多因素干预：基于肠促胰岛素的治疗方法的前景。
J Endocrinol Invest. 2011 Jan;34(1):69-77. doi: 10.1007/BF03346698. Epub 2011 Jan 13.
7
Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion.尽管预计西他列汀或二甲双胍治疗会减少尿糖排泄，但不会增加体重。
J Diabetes Sci Technol. 2009 Jan;3(1):68-82. doi: 10.1177/193229680900300108.
8
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice.胰高血糖素样肽 1 受体是仓鼠和小鼠餐后脂蛋白合成和分泌所必需的。
Diabetologia. 2010 Mar;53(3):552-61. doi: 10.1007/s00125-009-1611-5. Epub 2009 Dec 3.
9
Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.胰高血糖素样肽-1、糖尿病与心血管风险的未来展望
Nutr Metab Cardiovasc Dis. 2008 Nov;18(9):639-45. doi: 10.1016/j.numecd.2008.08.002. Epub 2008 Oct 11.
10
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.二肽基肽酶-4抑制剂西他列汀单药治疗对2型糖尿病患者血糖控制的影响。
Diabetes Care. 2006 Dec;29(12):2632-7. doi: 10.2337/dc06-0703.
Zotero 插件